Arvinas ARVN Stock
Arvinas Price Chart
Arvinas ARVN Financial and Trading Overview
| Arvinas stock price | 9.21 USD |
| Previous Close | 29.4 USD |
| Open | 29.04 USD |
| Bid | 0 USD x 900 |
| Ask | 0 USD x 800 |
| Day's Range | 28.38 - 30.65 USD |
| 52 Week Range | 21.21 - 58.58 USD |
| Volume | 466.76K USD |
| Avg. Volume | 467.94K USD |
| Market Cap | 1.62B USD |
| Beta (5Y Monthly) | 1.758609 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.82 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 71.1 USD |
ARVN Valuation Measures
| Enterprise Value | 501.07M USD |
| Trailing P/E | N/A |
| Forward P/E | -3.9186049 |
| PEG Ratio (5 yr expected) | 0.17 |
| Price/Sales (ttm) | 11.787289 |
| Price/Book (mrq) | 3.16961 |
| Enterprise Value/Revenue | 3.647 |
| Enterprise Value/EBITDA | -1.745 |
Trading Information
Arvinas Stock Price History
| Beta (5Y Monthly) | 1.758609 |
| 52-Week Change | -20.91% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 58.58 USD |
| 52 Week Low | 21.21 USD |
| 50-Day Moving Average | 25.38 USD |
| 200-Day Moving Average | 34.89 USD |
ARVN Share Statistics
| Avg. Volume (3 month) | 467.94K USD |
| Avg. Daily Volume (10-Days) | 648.01K USD |
| Shares Outstanding | 53.4M |
| Float | 44.02M |
| Short Ratio | 8.21 |
| % Held by Insiders | 9.52% |
| % Held by Institutions | 96.50% |
| Shares Short | 3.35M |
| Short % of Float | 7.23% |
| Short % of Shares Outstanding | 6.27% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -219.067% |
| Operating Margin (ttm) | -213.39% |
| Gross Margin | 100.00% |
| EBITDA Margin | -209.025% |
Management Effectiveness
| Return on Assets (ttm) | -13.75% |
| Return on Equity (ttm) | -48.77% |
Income Statement
| Revenue (ttm) | 137.4M USD |
| Revenue Per Share (ttm) | 2.58 USD |
| Quarterly Revenue Growth (yoy) | 22.60% |
| Gross Profit (ttm) | 131.4M USD |
| EBITDA | -287200000 USD |
| Net Income Avi to Common (ttm) | -301000000 USD |
| Diluted EPS (ttm) | -5.96 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 1.12B USD |
| Total Cash Per Share (mrq) | 21.04 USD |
| Total Debt (mrq) | 5M USD |
| Total Debt/Equity (mrq) | 0.98 USD |
| Current Ratio (mrq) | 4.059 |
| Book Value Per Share (mrq) | 9.569 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -307600000 USD |
| Levered Free Cash Flow (ttm) | -53950000 USD |
Profile of Arvinas
| Country | United States |
| State | CT |
| City | New Haven |
| Address | 5 Science Park |
| ZIP | 06511 |
| Phone | 203 535 1456 |
| Website | https://www.arvinas.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 415 |
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Q&A For Arvinas Stock
What is a current ARVN stock price?
Arvinas ARVN stock price today per share is 9.21 USD.
How to purchase Arvinas stock?
You can buy ARVN shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Arvinas?
The stock symbol or ticker of Arvinas is ARVN.
Which industry does the Arvinas company belong to?
The Arvinas industry is Biotechnology.
How many shares does Arvinas have in circulation?
The max supply of Arvinas shares is 68.77M.
What is Arvinas Price to Earnings Ratio (PE Ratio)?
Arvinas PE Ratio is now.
What was Arvinas earnings per share over the trailing 12 months (TTM)?
Arvinas EPS is -2.82 USD over the trailing 12 months.
Which sector does the Arvinas company belong to?
The Arvinas sector is Healthcare.
Arvinas ARVN included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 17366.13 USD — |
-0.1
|
9.58B USD — | 17128.71 USD — | 17467.35 USD — | — - | 9.58B USD — |
| Nasdaq US 700 Small Cap Index NQUS700SC | 2076.39 USD — |
+0.55
|
— — | 2051.38 USD — | 2085.49 USD — | — - | — — |
| Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG | 2765.32 USD — |
+0.46
|
— — | 2735.39 USD — | 2775.41 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4184.77 USD — |
+1.29
|
— — | 4144.83 USD — | 4202.15 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 931.02 USD — |
+0.81
|
— — | 921.75 USD — | 934.48 USD — | — - | — — |
| NASDAQ Global Select Market Com NQGS | 8495.19 USD — |
-0.11
|
— — | 8378.66 USD — | 8543.96 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4157.43 USD — |
+0.21
|
— — | 3927.42 USD — | 4157.43 USD — | — - | — — |
- {{ link.label }} {{link}}